Cartesian Therapeutics, Inc. (RNAC)
10.17
+0.13
(+1.29%)
USD |
NASDAQ |
Aug 24, 16:00
10.17
0.00 (0.00%)
After-Hours: 20:00
Cartesian Therapeutics Enterprise Value : 217.83M for Aug. 21, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 21, 2026 | 217.83M |
| August 20, 2026 | 223.54M |
| August 19, 2026 | 231.35M |
| August 18, 2026 | 192.60M |
| August 17, 2026 | 192.00M |
| August 14, 2026 | 181.78M |
| August 13, 2026 | 178.18M |
| August 12, 2026 | 176.83M |
| August 11, 2026 | 174.12M |
| August 10, 2026 | 179.38M |
| August 07, 2026 | 182.08M |
| August 06, 2026 | 179.38M |
| August 05, 2026 | 167.06M |
| August 04, 2026 | 158.35M |
| August 03, 2026 | 152.65M |
| July 31, 2026 | 150.54M |
| July 30, 2026 | 148.44M |
| July 29, 2026 | 139.13M |
| July 28, 2026 | 146.04M |
| July 27, 2026 | 150.24M |
| July 24, 2026 | 152.95M |
| July 23, 2026 | 154.15M |
| July 22, 2026 | 160.46M |
| July 21, 2026 | 160.46M |
| July 20, 2026 | 161.96M |
| Date | Value |
|---|---|
| July 17, 2026 | 164.36M |
| July 16, 2026 | 166.46M |
| July 15, 2026 | 176.98M |
| July 14, 2026 | 175.17M |
| July 13, 2026 | 175.47M |
| July 10, 2026 | 200.41M |
| July 09, 2026 | 206.71M |
| July 08, 2026 | 224.14M |
| July 07, 2026 | 218.13M |
| July 06, 2026 | 226.84M |
| July 02, 2026 | 234.35M |
| July 01, 2026 | 222.03M |
| June 30, 2026 | 229.24M |
| June 29, 2026 | 168.38M |
| June 26, 2026 | 162.11M |
| June 25, 2026 | 148.12M |
| June 24, 2026 | 168.38M |
| June 23, 2026 | 183.80M |
| June 22, 2026 | 177.23M |
| June 18, 2026 | 168.10M |
| June 17, 2026 | 175.24M |
| June 16, 2026 | 151.54M |
| June 15, 2026 | 138.70M |
| June 12, 2026 | 164.67M |
| June 11, 2026 | 123.28M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Allogene Therapeutics, Inc. | 468.18M |
| Beam Therapeutics, Inc. | 2.168B |
| C4 Therapeutics, Inc. | 294.82M |
| Kyverna Therapeutics, Inc. | 351.99M |
| Arrowhead Pharmaceuticals, Inc. | 12.07B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 13.72M |
| Total Expenses (Quarterly) | -13.72M |
| EPS Diluted (Quarterly) | 0.4595 |
| Earnings Yield | -58.40% |
| Normalized Earnings Yield | -39.89 |